The weak financials (revenue collapse, widening loss) are secondary to the STRO-004 clinical data, which provides the first proof-of-concept for Sutro's platform. The stock will likely trade on the clinical signal's perceived credibility vs. the cash burn rate. Watch for expansion cohort initiation in H1 2027 and the STRO-006 Phase 1 start in Q3 2026 as the next catalysts.
Price Chart
Executive Summary
Sutro Biopharma reported Q2 2026 revenue of $9.8M (down 84.6% YoY from $63.7M) and a net loss of $38.5M (-$2.33 EPS), significantly worse than the consensus estimate of -$2.27 EPS. The revenue decline reflects the absence of large upfront collaboration payments that boosted the prior-year period. However, the filing's primary market-moving content is the early clinical data for STRO-004, showing confirmed partial responses and a favorable tolerability profile, which validates the platform and supports pipeline progression despite the weak financials.
Key Financial Metrics
Key Facts
- Q2 2026 revenue was $9.8M, down 84.6% from $63.7M in Q2 2025, driven by the absence of large upfront collaboration payments.
- Net loss widened to $38.5M (-$2.33 EPS) vs. $11.5M (-$1.35 EPS) a year ago, missing consensus EPS of -$2.27.
- Cash, cash equivalents and marketable securities were $164.3M as of June 30, 2026, down from $202.6M at March 31, 2026.
- STRO-004 Phase 1 data showed confirmed and unconfirmed partial responses across three tumor types with a favorable tolerability profile; dose optimization ongoing at 4-5 mg/kg.
- STRO-006 (ITGB6-targeting ADC) on track for Phase 1 initiation in Q3 2026; STRO-227 dual-payload ADC IND submission targeted for 2026.
- Astellas collaboration milestone payment of $10M received in April 2026; second dual-payload iADC program expected to enter clinic in H2 2026.
- Cash runway expected to support operations into at least Q2 2028.
Financial Impact
Revenue declined $53.9M YoY; net loss worsened by $27.0M; cash burn of ~$38.3M in Q2 2026.
Risk Factors
- Revenue heavily dependent on collaboration milestones, which are lumpy and unpredictable.
- Cash burn of ~$38M/quarter implies ~4 quarters of runway before needing additional financing.
- STRO-004 is still in early dose optimization; expansion cohort data not expected until H1 2027, leaving a long catalyst gap.
- Competitive landscape for TF-targeting ADCs includes more advanced programs (e.g., I-Mab's, others).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343515 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | 8-K | $21.30 $17.83 | ▼ −16.29% | ▼ −14.39% | $15.32 (−28.08%) |
Aug 12, 2026 7w ago | Press Release | $21.30 $17.83 | ▼ −16.29% | ▼ −14.39% | $15.32 (−28.08%) |
Apr 22, 2026 23w ago | DEFA14A | $34.83 $31.13 | ▼ −10.62% | ▼ −15.26% | $15.32 (−56.01%) |
Apr 19, 2026 23w ago | Press Release | $34.58 $34.48 | ▼ −0.29% | ▼ −4.49% | $15.32 (−55.70%) |
Mar 23, 2026 27w ago | S-3 | $23.57 $35.53 | ▼ −50.74% | ▼ −41.84% | $15.32 (+35.00%) |
Mar 23, 2026 27w ago | Press Release | $23.57 $35.53 | ▲ +50.74% | ▲ +41.84% | $15.32 (−35.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access